Advertisement

Regulatory Considerations of Orthobiologic Procedures

  • Author Footnotes
    1 Present address: 1441 Clifton Road, Atlanta, GA 30322.
    Kudo Jang
    Footnotes
    1 Present address: 1441 Clifton Road, Atlanta, GA 30322.
    Affiliations
    Department of Physical Medicine and Rehabilitation, Emory University School of Medicine, Atlanta, GA, USA
    Search for articles by this author
  • Author Footnotes
    2 Present address: 1968 Hawks Lane, Atlanta, GA 30329.
    ,
    Author Footnotes
    3 Present address: 1500 Owens Street; San Francisco, CA 94158
    William A. Berrigan
    Footnotes
    2 Present address: 1968 Hawks Lane, Atlanta, GA 30329.
    3 Present address: 1500 Owens Street; San Francisco, CA 94158
    Affiliations
    Department of Orthopaedics, University of California San Francisco, CA, USA
    Search for articles by this author
  • Ken Mautner
    Correspondence
    Corresponding author. 1968 Hawks Lane, Atlanta, GA 30329.
    Affiliations
    Department of Physical Medicine and Rehabilitation, Emory University School of Medicine, Atlanta, GA, USA

    Department of Orthopedics, Emory University School of Medicine, Atlanta, GA, USA
    Search for articles by this author
  • Author Footnotes
    1 Present address: 1441 Clifton Road, Atlanta, GA 30322.
    2 Present address: 1968 Hawks Lane, Atlanta, GA 30329.
    3 Present address: 1500 Owens Street; San Francisco, CA 94158
Published:October 17, 2022DOI:https://doi.org/10.1016/j.pmr.2022.08.016

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Physical Medicine and Rehabilitation Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bauer G.
        • Elsallab M.
        • Abou-El-Enein M.
        Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions.
        Stem Cells Transl Med. 2018; 7: 676-685
        • Murdoch C.E.
        • Scott C.T.
        Stem cell tourism and the power of hope.
        Am J Bioeth. 2010; 10: 16-23
        • Caulfield T.
        • Sipp D.
        • Murry C.E.
        • et al.
        SCIENTIFIC COMMUNITY. Confronting stem cell hype.
        Science. 2016; 352: 776-777
        • Shapiro S.A.
        • Finnoff J.T.
        • Awan T.M.
        • et al.
        Highlights from the American Medical Society for Sports Medicine position statement on responsible use of regenerative medicine and orthobiologics in sports medicine.
        Br J Sports Med. 2022; 56: 121-122
        • Berger I.
        • Ahmad A.
        • Bansal A.
        • et al.
        Global Distribution of Businesses Marketing Stem Cell-Based Interventions.
        Cell Stem Cell. 2016; 19: 158-162
        • Arango-Rodriguez M.L.
        • Ezquer F.
        • Ezquer M.
        • et al.
        Could cancer and infection be adverse effects of mesenchymal stromal cell therapy?.
        World J Stem Cells. 2015; 7: 408-417
        • Turner L.
        • Knoepfler P.
        Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
        Cell Stem Cell. 2016; 19: 154-157
      1. Research USDoHaHSFaDACfBEa. Guidance for Industry: Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Small Entity Compliance Guide. 2007.

      2. Title 21 Code of Federal Regulations Part 1271 Human Cells, Tissues, and Cellular and Tissue-Based Products.

      3. Establishment registration and listing for manufacturers of human cellular and tissue-based products--FDA. Proposed rule.
        Fed Regist. 1998; 63: 26744-26755
        • Sipp D.
        Direct-to-consumer stem cell marketing and regulatory responses.
        Stem Cells Transl Med. 2013; 2: 638-640
        • US Department of Health and Human Services FaDA
        Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use.
        • Fang W.H.
        • Vangsness Jr., C.T.
        Food and Drug Administration's Position on Commonly Injected Biologic Materials in Orthopaedic Surgery.
        Am J Sports Med. 2021; 49: 3414-3421
        • Huebner K.
        • Frank R.M.
        • Getgood A.
        Ortho-Biologics for Osteoarthritis.
        Clin Sports Med. 2019; 38: 123-141
        • Marx R.E.
        Platelet-rich plasma (PRP): what is PRP and what is not PRP?.
        Implant Dent. 2001; 10: 225-228
        • Beitzel K.
        • Allen D.
        • Apostolakos J.
        • et al.
        US definitions, current use, and FDA stance on use of platelet-rich plasma in sports medicine.
        J Knee Surg. 2015; 28: 29-34
        • Arshi A.
        • Petrigliano F.A.
        • Williams R.J.
        • et al.
        Stem Cell Treatment for Knee Articular Cartilage Defects and Osteoarthritis.
        Curr Rev Musculoskelet Med. 2020; 13: 20-27
        • Jones I.A.
        • Togashi R.C.
        • Thomas Vangsness Jr., C.
        The Economics and Regulation of PRP in the Evolving Field of Orthopedic Biologics.
        Curr Rev Musculoskelet Med. 2018; 11: 558-565
        • Sweet B.V.
        • Schwemm A.K.
        • Parsons D.M.
        Review of the processes for FDA oversight of drugs, medical devices, and combination products.
        J Manag Care Pharm. 2011; 17: 40-50
        • Kim G.B.
        • Seo M.-S.
        • Park W.T.
        • et al.
        Bone Marrow Aspirate Concentrate: Its Uses in Osteoarthritis.
        Int J Mol Sci. 2020; 21: 3224
        • Veronesi F.
        • Giavaresi G.
        • Tschon M.
        • et al.
        Clinical use of bone marrow, bone marrow concentrate, and expanded bone marrow mesenchymal stem cells in cartilage disease.
        Stem Cells Dev. 2013; 22: 181-192
        • Heidari N.
        • Borg T.M.
        • Olgiati S.
        • et al.
        Microfragmented Adipose Tissue Injection (MFAT) May Be a Solution to the Rationing of Total Knee Replacement: A Prospective, Gender-Bias Mitigated, Reproducible Analysis at Two Years.
        Stem Cells Int. 2021; 2021: 9921015
        • Heidari N.
        • Noorani A.
        • Slevin M.
        • et al.
        Patient-Centered Outcomes of Microfragmented Adipose Tissue Treatments of Knee Osteoarthritis: An Observational, Intention-to-Treat Study at Twelve Months.
        Stem Cells Int. 2020; 2020: 8881405
        • Ude C.C.
        • Sulaiman S.B.
        • Min-Hwei N.
        • et al.
        Cartilage regeneration by chondrogenic induced adult stem cells in osteoarthritic sheep model.
        PLoS One. 2014; 9: e98770
        • Guercio A.
        • Di Marco P.
        • Casella S.
        • et al.
        Production of canine mesenchymal stem cells from adipose tissue and their application in dogs with chronic osteoarthritis of the humeroradial joints.
        Cell Biol Int. 2012; 36: 189-194
        • Bacakova L.
        • Zarubova J.
        • Travnickova M.
        • et al.
        Stem cells: their source, potency and use in regenerative therapies with focus on adipose-derived stem cells - a review.
        Biotechnol Adv. 2018; 36: 1111-1126
        • Jurgens W.J.
        • Oedayrajsingh-Varma M.J.
        • Helder M.N.
        • et al.
        Effect of tissue-harvesting site on yield of stem cells derived from adipose tissue: implications for cell-based therapies.
        Cell Tissue Res. 2008; 332: 415-426
        • Oedayrajsingh-Varma M.J.
        • van Ham S.M.
        • Knippenberg M.
        • et al.
        Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure.
        Cytotherapy. 2006; 8: 166-177
        • Desando G.
        • Bartolotti I.
        • Martini L.
        • et al.
        Regenerative Features of Adipose Tissue for Osteoarthritis Treatment in a Rabbit Model: Enzymatic Digestion Versus Mechanical Disruption.
        Int J Mol Sci. 2019; 20: 2636
        • Malanga G.A.
        • Bemanian S.
        Microfragmented adipose injections in the treatment of knee osteoarthritis.
        J Clin Orthop Trauma. 2019; 10: 46-48
      4. FDA Office of Communication O, (OCOD) aD. Same Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception. Accessed May 2022.

        • Heikkinen J.
        • Mottonen M.
        • Pulkki K.
        • et al.
        Cytokine levels in midtrimester amniotic fluid in normal pregnancy and in the prediction of pre-eclampsia.
        Scand J Immunol. 2001; 53: 310-314
        • Chow S.S.
        • Craig M.E.
        • Jones C.A.
        • et al.
        Differences in amniotic fluid and maternal serum cytokine levels in early midtrimester women without evidence of infection.
        Cytokine. 2008; 44: 78-84
        • Bennett N.T.
        • Schultz G.S.
        Growth factors and wound healing: biochemical properties of growth factors and their receptors.
        Am J Surg. 1993; 165: 728-737
        • Korenovsky Y.V.
        • Remneva O.V.
        [Reference ranges of matrix metalloproteinase-1, -2, -9 and tissue inhibitor of matrix metalloproteinases-1 concentrations in amniotic fluid in physiological pregnancy].
        Biomed Khim. 2016; 62: 96-98
        • Meinert M.
        • Eriksen G.V.
        • Petersen A.C.
        • et al.
        Proteoglycans and hyaluronan in human fetal membranes.
        Am J Obstet Gynecol. 2001; 184: 679-685
        • Lee T.Y.
        • Schafer I.A.
        Glycosaminoglycan composition of human amniotic fluid.
        Biochim Biophys Acta. 1974; 354: 264-274
        • Panero A.J.
        • Hirahara A.M.
        • Andersen W.J.
        • et al.
        Are Amniotic Fluid Products Stem Cell Therapies? A Study of Amniotic Fluid Preparations for Mesenchymal Stem Cells With Bone Marrow Comparison.
        Am J Sports Med. 2019; 47: 1230-1235
        • Dresser R.
        Ethical issues in embryonic stem cell research.
        JAMA. 2001; 285: 1439-1440
      5. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use (2020).

        • FDA
        FDA Extends Enforcement Discretion Policy for Certain Regenerative Medicine Products.
        (Available at:) (Accessed April 4, 2022)
        • Finnoff J.T.
        • Awan T.M.
        • Borg-Stein J.
        • et al.
        American Medical Society for Sports Medicine Position Statement: Principles for the Responsible Use of Regenerative Medicine in Sports Medicine.
        Clin J Sport Med. 2021; 31: 530-541